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Abstract
Introduction: Germline variants in TP63 have been consistently associated with several tumors, including bladder cancer,
indicating the importance of TP53 pathway in cancer genetic susceptibility. However, variants in other related genes,
including TP53 rs1042522 (Arg72Pro), still present controversial results. We carried out an in depth assessment of
associations between common germline variants in the TP53 pathway and bladder cancer risk.
Material and Methods: We investigated 184 tagSNPs from 18 genes in 1,058 cases and 1,138 controls from the Spanish
Bladder Cancer/EPICURO Study. Cases were newly-diagnosed bladder cancer patients during 1998–2001. Hospital controls
were age-gender, and area matched to cases. SNPs were genotyped in blood DNA using Illumina Golden Gate and TaqMan
assays. Cases were subphenotyped according to stage/grade and tumor p53 expression. We applied classical tests to assess
individual SNP associations and the Least Absolute Shrinkage and Selection Operator (LASSO)-penalized logistic regression
analysis to assess multiple SNPs simultaneously.
Results: Based on classical analyses, SNPs in BAK1 (1), IGF1R (5), P53AIP1 (1), PMAIP1 (2), SERINPB5 (3), TP63 (3), and TP73 (1)
showed significant associations at p-value#0.05. However, no evidence of association, either with overall risk or with
specific disease subtypes, was observed after correction for multiple testing (p-value$0.8). LASSO selected the SNP
rs6567355 in SERPINB5 with 83% of reproducibility. This SNP provided an OR = 1.21, 95%CI 1.05–1.38, p-value = 0.006, and a
corrected p-value = 0.5 when controlling for over-estimation.
Discussion: We found no strong evidence that common variants in the TP53 pathway are associated with bladder cancer
susceptibility. Our study suggests that it is unlikely that TP53 Arg72Pro is implicated in the UCB in white Europeans.
SERPINB5 and TP63 variation deserve further exploration in extended studies.
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Introduction
In more developed countries, urothelial carcinoma of the
bladder (UCB) is the fourth most common cancer in men and the
seventeenth in women, the overall male:female ratio being 3:1.
This ratio is greater (6:1) in Spain, where the disease presents one
of the highest incidence rates among men (51 per 100,000 man-
year) [1]. Tobacco smoking and occupational exposure to
aromatic amines have been established as the strongest risk
factors, among others [2]. While no high-penetrance allele/gene
has been identified to date as associated with UCB, there is well-
established evidence that UCB risk is influenced by common
genetic variants [3,4].
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Previous studies characterizing UCB are consistent with the
existence of, at least, two disease subtypes based on their
morphological and genetic features. The first subtype includes
low-risk, papillary, non-muscle invasive tumors (NMIT, 60–65%
of all UCB) and the second type includes both high-risk NMIT
(15–20% of all UCB) and muscle invasive tumors (MIT, 20%–
30% of all UCB). Supporting these morphological subtypes,
differential genetic pathways were described and were associated
with distinct UCB evolution. Somatic mutations in FGFR3 are
more frequent in low-risk NMIT, while mutations in TP53 and RB
are mainly involved in high-risk NMIT and MIT [5,6]; mutations
in PIK3CA and HRAS occur similarly in the two tumor subtypes.
Interestingly, an exploratory analysis has shown that some
germline genetic variants might be differentially associated with
the risk of developing distinct UCB subphenotypes defined
according to tumor stage (T) and grade (G) [7].
TP53 is the most important human tumor suppressor gene and
its implications in UCB have been extensively studied [8]. TP53 is
located in17p13, a region that is frequently deleted in human
cancers, and it encodes the p53 protein. p53 is a transcription
factor controlling cell proliferation, cell cycle, cell survival, and
genomic integrity and - therefore - it regulates a large number of
genes. Under normal cellular conditions, p53 is rapidly degraded
due to the activity ofMDM2, a negative p53 regulator that is also a
p53 target gene. Upon DNA damage or other stresses, p53 is
stabilized and regulates the expression of many genes involved in
cell cycle arrest, apoptosis, and DNA repair among others.
Somatic alterations in TP53/p53 are one of the most frequent
alterations associated with UCB, especially with the more
aggressive tumors [9].
Germline TP53 mutations predispose to a wide spectrum of
early-onset cancers and cause Li-Fraumeni and related syndromes
[10,11]. These mutations are usually single-base substitutions.
Over 200 germline single nucleotide polymorphisms (SNPs) in
TP53 have been identified at present [12]. SNP rs1042522
(Arg72Pro) has been assessed in association with several cancers,
among them UCB. However, the results of these studies are
inconsistent [13,14,15,16,17,18]. In contrast, an association
between SNP rs710521 in TP63, a TP53 family member, and
risk of UCB has been convincingly replicated, pointing to the
involvement of TP53 pathway members in UCB susceptibility [4].
The aim of this study was to comprehensively investigate
whether germline SNPs in genes involved in the TP53 pathway are
associated with risk of UCB. To this end, a total of 184 tagSNPs in
18 key genes were assessed using data from the Spanish Bladder
Cancer/EPICURO study.
Materials and Methods
Study Subjects
The Spanish Bladder Cancer/EPICURO Study is a case-
control study carried out in 18 hospitals from five areas in Spain
and described elsewhere [2,4,7]. Briefly, cases were patients
diagnosed with primary UCB at age 21–80 years between 1998
and 2001. All participants were of self-reported white European
ancestry. Diagnostic slides from each patient were reviewed by a
panel of expert pathologists to confirm the diagnosis and to ensure
that uniform classification criteria were applied based on the 1999
World Health Organization and International Society of Urolog-
ical Pathology systems [19].
Controls were patients admitted to participating hospitals for
conditions thought to be unrelated to the UCB risk factors. The
main reasons for hospital admission were: hernia (37%), other
abdominal surgery (11%), fracture (23%), other orthopaedic
problem (7%), hydrocoele (12%), circulatory disorder (4%),
dermatological disorder (2%), ophthalmological disorder (1%),
and other diseases (3%). Controls were individually matched to the
cases on age within 5-year categories, gender, ethnic origin and
region of residence.
Information on sociodemographics, smoking habits, occupa-
tional and environmental exposures, and past medical and familial
history of cancer was collected by trained study monitors who
conducted a comprehensive computer- assisted personal interview
with the study participants during their hospital stay. Of 1,457
eligible cases and 1,465 controls, 1,219 (84%) and 1,271 (87%),
were interviewed, respectively.
All subjects gave written informed consent to participate in the
study, which was approved by the ethics committees of the
participating centers.
Genotyping
A total of 184 tagSNPs from 18 genes participating in the TP53
pathway were selected using the Select Your SNPs (SYSNPs)
program [20]. SYSNP used information from dbSNP b25, hg17
and HapMap Release #21. Haploview’s Tagger algorithm (v3.32)
was applied with default parameter values. The tool considers all
available information for each SNP and implements algorithms
that provide the status of each SNP as a tagSNP, a captured SNP
or a non-captured SNP. According to this information tagSNPs
were selected. The following groups of genes were considered: 1)
TP53 family members (TP53, TP63 and TP73) and 2) genes
known to be targets of p53 or regulators of p53 function [BAK1,
BAX, BBC3, BIRC5, CDKN1A, FAS, GADD45A, IGF1R, MDM2,
PCNA, PMAIP1, SERPINB5, SFN (Stratifin, 14-3-3sigma),
TP53AIP1), and 3) c-MYC, a major oncogene involved in a broad
range of human cancers that regulates p53 pro-apoptotic activity
(See Table S1 in File S1). SNPs were genotyped using Illumina
Golden Gate and TaqMan (Applied Biosystems) assays at the
Spanish Core Genotyping Facility at the CNIO (CEGEN- CNIO).
Genotyping was successful for 1,058 cases and 1,138 controls. We
calculated the coverage for each gene using Haploview 4.2 by
selecting the SNPs within a gene with a MAF$0.05 from the 1000
genomes project, as reference, and obtained the number of SNPs
captured with the SNPs genotyped at r2$0.8 within each gene.
Statistical Analysis
Departure from Hardy-Weinberg equilibrium was assessed in
controls using Pearson’s chi-squared test. Missing genotypes were
imputed for the multi-SNP model using the BEAGLE 3.0 method
[21]. Associations between UCB and the SNPs considered were
assessed using two approaches: classical logistic and polytomous
regression analyses applied to each SNP individually, and the
Least Absolute Shrinkage and Selection Operator (LASSO)-
penalized logistic regression to assess all SNPs simultaneously.
All models were adjusted for age at diagnosis (cases) or interview
(controls), gender, region, and smoking status. Smoking status was
coded in four categories (never: ,100 cigarettes in their lifetime;
occasional: at least one per day for $6 months; former: if they had
smoked regularly, but stopped at least 1 year before the study
inclusion date; and current: if they had smoked regularly within a
year of the inclusion date [2].
With the ‘‘classical’’ statistical approaches we assessed SNP
main effects for the whole disease and for different subtypes of
UCB, as well as SNP*SNP and SNP*smoking interactions. Disease
subtypes were defined in two ways. First, according to established
criteria based on tumor stage (T) and grade (G) as low-risk NMIT
(TaG1 and TaG2), high-risk NMIT (TaG3, T1G2, T1G3, and
Tis), and MIT (T2, T3, and T4); and second, according to the
TP53 Pathway and Bladder Cancer Susceptibility
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tumor expression of p53 determined using DO7 antibody. We
applied the histoscore as z~
P3
i~1
i  pos%cellsi, where pos%cellsi
was the percentage of cells with intensity i(i~1,2,3). We then
classified cases as having low or high p53 expression relative to the
median histoscore.
To assess overall main effects, the four modes of inheritance
were considered: co- dominant, dominant, recessive, and additive.
The statistical significance of associations was determined using
the Likelihood Ratio Test (LRT). We evaluated associations
between individual SNPs and subtypes of UCB using polytomous
logistic regression. Heterogeneity by disease subtype was tested by
a LRT comparing this model to that with the ln(OR) restricted to
be equal across subtypes. We also evaluated all two-way
interactions between SNPs by a LRT comparing logistic regression
models with the two SNPs (additive model) and covariates
described above, with and without a single interaction term for
multiplicative, per-allele effects. Interactions between each SNP
and cigarette use (never vs. ever) were assessed using a similar
method. Multiple testing was accounted for by applying a
permutation test with 1,000 replicates. We applied Quanto
(http://hydra.usc.edu/gxe/) to assess statistical power considering
the available sample size.
We also assessed combined SNP effects using LASSO. The
method has been described in detail by [22]. Briefly, the log-
likelihood function applied in classical logistic regression
Ln bð Þ
Xn
i~1
yi logp X ’ibð Þz 1{yið Þlog 1{p X ’ibð Þð Þ½ , ð1Þ
where n is the number of observations, is reconstructed incorpo-
rating a penalty so that
g(b; l)~Ln(b)zl
Xp
j~1
bj
 , ð2Þ
where p is the number of SNPs and l is the lasso penalty. The
Newton-Raphson algorithm is applied to equation (2) to estimate
b’s in an iterative way.
The LASSO method is based on the idea of removing irrelevant
predictor variables (b=0) via the penalty parameter, thereby
selecting only the most relevant SNPs as the subset of markers
most associated with the disease. The application of the penalty
parameter also avoids overfitting due to both high-dimensionality
and collinearity between covariates. We only considered additive
genetic mode of inheritance.
This technique gives biased estimators to reduce their variance.
Because of this, the implemented package in R does not provide
estimates p-values for the regression beta coefficients, since
standard errors are not meaningful under a biased estimator.
We therefore evaluated the results by first applying the LASSO
using a 5-fold cross-validation (CV) method [23] to choose the
optimal l as that giving the minimum Akaike information
criterion (AIC); we then selected the subset of SNPs that were
most informative with that l. We assessed the robustness of each
SNP selected in the optimal model by calculating the reproduc-
ibility as the proportion of times each SNP was selected to be in
the multivariate model from 1,000 bootstrap subsamples [24].
To evaluate the association with UCB risk of that subset of
SNPs, we tested them by the LRT in a multivariate regression
Table 1. Demographics and smoking status of patients included in the study.
Cases (n = 1058) Controls (n = 1138) 1p-value
Gender
Male 920 (87%) 991 (87%)
Female 138 (13%) 147 (13%) 0.9
Age
,55 149 (14%) 181 (16%)
55–64 222 (21%) 278 (24%)
65–69 241 (23%) 263 (23%)
70–74 225 (21%) 222 (20%)
75+ 221 (21%) 194 (17%) 0.06
Region
1-Barcelona 214 (20%) 233 (21%)
2-Valles 173 (16%) 181 (16%)
3-Elche 83 (8%) 80 (7%)
4-Tenerife 195 (19%) 207 (18%)
5-Asturias 393 (37%) 437 (38%) 0.9
Smoking
Never 147 (14%) 334 (29%)
Occasional 43 (4%) 81 (7%)
Former 409 (38%) 429 (38%)
Current 454 (43%) 283 (25%) ,0.001
Missing 5 (1%) 11 (1%)
1p-value from Pearson’s x2 test for association.
doi:10.1371/journal.pone.0089952.t001
TP53 Pathway and Bladder Cancer Susceptibility
PLOS ONE | www.plosone.org 3 May 2014 | Volume 9 | Issue 5 | e89952
model with all the SNPs in comparison to the null model. To
correct for the over-estimation due the pre-selection of the best
SNPs, we performed a permutation test with 10,000 replicates.
STATA 10 was used to run the classical logistic and
multinomial regression analyses. All other statistical analyses were
run in R (http://www.R-project.org), using the penalized library
[25] for LASSO penalized logistic regression.
Results
Table 1 shows the distribution of the study subjects included in
the analysis: 1,058 cases and 1,138 controls. Most individuals
(87%) were male and cases were more likely to be current smokers
than controls (43% vs. 25%, respectively, p-value,0.001).
No evidence of departure from Hardy-Weinberg equilibrium
was observed for any SNPs after consideration of multiple testing
(unadjusted p-value.1024). Polymorphisms in TP53 were not
individually associated with UCB risk, even at a nominal,
uncorrected 5% significance level (uncorrected p-value.0.4).
The percentage of reproducibility from the LASSO model using
1,000 bootstrap subsamples was ,50%, indicating a poor
robustness of the models. Results for the additive and co-dominant
models are summarized in Table 2.
Using classical logistic regression, SNPs in BAK1 (1), IGF1R (5),
P53AIP1 (1), PMAIP1 (2), SERPINB5 (3), TP63 (3), and TP73 (1)
showed significant results, at a non-corrected p-value#0.05, with
overall UCB risk (Table 3). However, no evidence of association
with risk was observed for any individual SNPs after correcting for
multiple testing (permutation test p-value.0.8). This was also the
case for the associations with the established disease subtypes
defined according to stage/grade or by p53 expression (Figure 1).
Of note, SNPs rs3758483 and rs983751 in FAS were differentially
and inversely associated with MIT and high p53 expressing
tumors in uncorrected analyses (Tables S2 and S3 in File S1). We
also observed no evidence of SNP*SNP interactions or interactions
between SNPs and smoking status (data not shown).
When all 184 SNPs were simultaneously assessed using LASSO,
the method selected rs6567355 in SERPINB5 with a reproducibil-
ity = 83%. This SNP provided an OR=1.21, 95%CI 1.05–1.38,
p-value = 0.006 in the main effect logistic regression model and a
corrected p-value = 0.5 when controlling for over-estimation
(Table 3). While not selected by LASSO in the last model under
the stringent criteria applied, IGF1R-rs1058696 (OR=0.63,
95%CI 0.44–0.90, p-value = 0.010) and TP63-rs13321831
(OR=1.36, 95%CI 1.06–1.73, p-value = 0.014) showed a per-
centage of reproducibility .80%.
Discussion
We genotyped common variants in genes in the TP53 pathway
in 1,058 cases and 1,138 controls of white European ancestry and
found no strong evidence of association with risk of UCB overall,
or with subtypes of the disease defined by stage and grade or by
p53 expression.
A key gene in the pathway is TP53, and the most commonly
studied variant in this particular gene is Arg72Pro (rs1042522). Its
implication in susceptibility to various cancers has been reported
in Asian populations, but not in white Europeans. A meta- analysis
of 49 cervical cancer studies contributing a total of 7,946 cases and
7,888 controls found that the Arg allele was associated with an
increased risk of cervix cancer [14]. However, another meta-
analysis of 39 studies (26,041 cases and 29,679 controls) found
weak evidence for an association of the same variant with reduced
breast cancer risk [18]. Regarding gastric cancer, a combined
analysis of 6,859 cases and 9,277 controls from 28 studies found a
T
a
b
le
2
.
SN
P
s
in
TP
53
an
d
b
la
d
d
e
r
ca
n
ce
r
ri
sk
.
C
a
se
s
C
o
n
tr
o
ls
A
d
d
it
iv
e
m
o
d
e
l
C
o
-d
o
m
in
a
n
t
m
o
d
e
l
R
e
p
r.
(%
)
S
N
P
A
A
A
a
a
a
A
A
A
a
a
a
O
R
9
5
%
C
I
p
-v
al
u
e
O
R
(A
a
)
9
5
%
C
I
p
-v
al
u
e
O
R
(a
a
)
9
5
%
C
I
p
-v
al
u
e
P
-t
re
n
d
rs
1
0
4
2
5
2
2
1
5
8
8
3
7
2
7
2
6
2
8
3
8
8
8
4
1
.0
4
0
.9
1
–
1
.2
0
0
.5
1
.1
0
0
.9
1
–
1
.3
3
0
.3
0
.9
7
0
.6
8
–
1
.3
7
0
.8
0
.5
2
4
%
rs
1
2
9
5
1
0
5
3
9
1
5
1
0
9
3
9
7
2
1
2
2
5
0
.9
8
0
.7
5
–
1
.2
7
0
.9
1
.0
4
0
.7
9
–
1
.3
9
0
.7
0
.6
4
0
.1
4
–
2
.8
8
0
.5
0
.8
3
5
%
rs
1
6
2
5
8
9
5
7
6
1
2
4
1
2
8
7
9
3
2
6
6
2
6
1
.0
4
0
.8
8
–
1
.2
4
0
.6
0
.9
9
0
.8
0
–
1
.2
1
0
.9
1
.2
8
0
.7
3
–
2
.2
6
0
.4
0
.7
1
3
%
rs
2
2
8
7
4
9
7
8
3
5
1
8
3
9
8
6
9
2
0
7
1
1
0
.9
5
0
.7
7
–
1
.1
7
0
.7
0
.9
7
0
.7
7
–
1
.2
2
0
.8
0
.7
0
0
.2
8
–
1
.7
4
0
.4
0
.7
4
8
%
rs
2
9
0
9
4
3
0
7
4
9
2
5
1
2
8
8
0
0
2
7
2
2
7
1
.0
3
0
.8
7
–
1
.2
3
0
.7
1
.0
4
0
.8
5
–
1
.2
7
0
.7
1
.2
3
0
.7
0
–
2
.1
6
0
.5
0
.7
3
6
%
rs
8
0
7
3
4
9
8
4
2
5
4
6
7
1
3
2
4
3
5
5
2
1
1
2
8
0
.9
9
0
.8
7
–
1
.1
3
0
.9
0
.9
4
0
.7
8
–
1
.1
3
0
.5
1
.0
1
0
.7
5
–
1
.3
4
0
.9
0
.8
4
4
%
rs
8
0
7
9
5
4
4
9
2
3
1
0
3
2
9
9
3
1
0
2
4
1
.0
5
0
.7
9
–
1
.3
9
0
.7
1
.1
0
0
.8
1
–
1
.4
8
0
.5
0
.4
2
0
.0
7
–
2
.3
3
0
.3
0
.5
4
0
%
R
ep
r.
(%
),p
e
rc
e
n
ta
g
e
re
p
ro
d
u
ci
b
ili
ty
as
se
ss
in
g
th
e
ro
b
u
st
n
e
ss
o
f
e
ac
h
SN
P
b
y
LA
SS
O
.
A
A
,
A
a
an
d
aa
re
p
re
se
n
t
co
m
m
o
n
-h
o
m
o
zy
g
o
te
s,
h
e
te
ro
zy
g
o
te
s
an
d
ra
re
-a
lle
le
h
o
m
o
zy
g
o
te
s,
re
sp
e
ct
iv
e
ly
.
O
R
,
o
d
d
s
ra
ti
o
;
C
I,
co
n
fi
d
e
n
ce
in
te
rv
al
;
O
R
(A
a)
an
d
O
R
(a
a)
w
e
re
e
st
im
at
e
d
re
la
ti
ve
to
g
e
n
o
ty
p
e
A
A
.
1
A
rg
7
2
P
ro
p
o
ly
m
o
rp
h
is
m
.
A
ll
m
o
d
e
ls
w
e
re
ad
ju
st
e
d
fo
r
ag
e
,
g
e
n
d
e
r,
re
g
io
n
an
d
ci
g
ar
e
tt
e
sm
o
ki
n
g
st
at
u
s.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
8
9
9
5
2
.t
0
0
2
TP53 Pathway and Bladder Cancer Susceptibility
PLOS ONE | www.plosone.org 4 May 2014 | Volume 9 | Issue 5 | e89952
stronger inverse association only among Asians [26]. For lung
cancer, a marginally significant increased risk was in a combined
analysis of data with 15,647 cases and 14,391 controls from 36
studies, though the association seemed to be also confined to the
Asian population [27].
The association between TP53 Arg72Pro and UCB risk has
been assessed by two meta-analyses. Overall, no association was
observed by Jiang et al. when comparing 1,601 cases and 1,948
controls from 10 studies, although a marginally significant
association was seen among Asians (OR=0.77, 95%CI 0.59–
1.00, for ArgArg/ArgPro vs. ProPro) [13]. Discordant results have
been recently reported combining data from 14 studies contrib-
uting with 2,176 cases and 2,798 controls (OR=1.268, 95%CI
1.003–1.602, for ArgArg/ArgPro vs. ProPro among the Asian
population) [17]. A large number of studies overlap between the
two meta-analyses. The lack of information on gene-gene and
gene-environment interactions, as well as on the concomitant
effect of TP53 somatic mutations may explain the discordant
results [28].
The findings from our study confirm the lack of association of
Arg72Pro in TP53 with risk of UCB in white Europeans
(OR=0.98, 95%CI 0.77–1.26, for ArgPro vs. ArgArg and
OR=0.91, 95%CI 0.75–1.09, for ProPro vs. ArgArg, p-
value = 0.5 for overall effects) [13,17]. However, we cannot rule
out that lack of statistical power may hamper identification of a
small effect association: even with its large sample size, the present
study sample size could detect an OR$1.3 per-allele for this SNP
with 90% statistical power and at a significance level of 5%.
Regarding other SNPs in TP53, Lin et al reported an
association with rs9895829 and rs1788227 (p-value = 0.003 and
0.027, respectively) in a smaller study with 201 cases and 311
controls in an Asian population [29]. We did not genotype these
SNPs, though they are in high LD with two SNPs considered here:
rs8079544 (LD=1.0) and rs12951053 (LD=0.7), respectively.
Nonetheless, none of the assessed additional SNPs in TP53
appeared to be associated with UCB risk. The partial coverage of
the gene with the assessed SNPs (38%) does not allow us to dismiss
the role of TP53 in UCB susceptibility.
TP63 is another key member of the studied pathway. One SNP
(rs710521) located in this gene has been reported to be associated
with risk of UCB by a GWAS (per-allele OR=1.19, 95%CI 1.12–
1.27, p-value = 1.1561027) [30]. This association was convinc-
ingly replicated in a combined analysis of data from different
studies (allele-specific OR=1.18, 95%CI 1.12–1.24, p-val-
ue = 1.8610210), including ours, for which it was genotyped as
part of a separate initiative [4]. Of note, this particular SNP did
not show significant results in our study (OR=0.95, 95%CI 0.83–
1.10, p-value = 0.5), a fact that can be explained by the different
geographical location related exposures of the participating
studies, being UCB an environmental driven disease [31]. The
present study assessed 32 SNPs in TP63, providing 24% of the
gene coverage. Three of them showed uncorrected significant
results in the overall UCB association analysis with a percentage of
reproducibility .70% from LASSO. These results warrant an
extended UCB study on this region.
Regarding other SNPs in the selected genes, we did not find any
strong evidence of association after correcting for multiple testing
(permutation test p-value$0.8 for overall main effects and p-
value$0.3 for subtype effects). The top (uncorrected) significant
SNPs were located in BAK1, IGF1R, P53AIP1, PMAIP1,
SERPINB5, and TP73. Common variants in these genes have
not previously been reported as associated with UCB risk, though
an altered expression of BAK1 and IGF1R has been described in
bladder tumors.
Many complex diseases, such as UCB, are likely due to the
combined effects of multiple loci [32] and most traditional
association studies assessing main effects for one SNP at a time
are underpowered to detect small effects [33]. Therefore, the
implication of common genetic variants may be better assessed by
a method that both selects a far-reduced set of potentially
associated SNPs and tests for association globally. This has been
a challenge due to the high-dimensionality and collinearity
Figure 1. Main effect p-values for bladder cancer risk (overall and for each subphenotype) for each tag-SNP under the additive
mode of inheritance. A SNP p-value above the red line is considered as associated with the phenotype after multiple testing correction by
Bonferroni (4.2 for main effects and 3.6 for subtypes). All models are adjusted for age, gender, region and cigarette smoking status.
doi:10.1371/journal.pone.0089952.g001
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between SNPs. Nevertheless, penalized techniques can deal with
these problems and they are starting to emerge in genetic
association studies. Wu et al used penalized logistic regression in
a genome-wide association study applied to coeliac disease data
and Zhou et al extended this work to the assessment of association
for common and rare variants applied to family cancer registry
data [34] [35]. In the present study, we applied the LASSO
algorithm to account for the combination effects of the SNPs in the
TP53 pathway and UCB risk. Under the criteria applied, this
method selected one SNP (rs6567355) that showed a non-
corrected p-value = 0.006 for the additive mode of inheritance
with a percentage of reproducibility = 83%. This is a frequent G.
A SNP (MAF=0.29) located in the intron region of SERPINB5. As
mentioned before, no evidences of previous association between
this SNP and any disease have been reported at present.
SERPINB5 is a tumor suppressor (Table S1 in File S1). The
expression levels of this gene has been correlated with those of
DBC1 (Deleted in bladder cancer 1) in UCB specimens, suggesting
its involvement in the urokinase-plasminogen pathway [36].
SERPINB5 would deserve of further exploration in extended
studies, as well.
A limitation of our study is the incomplete tagging of the
selected genes due to the use of an earlier HapMap release to
select tag SNPs, prior to the availability of data from the 1000
genomes project. The median coverage of the 18 genes considered
in the pathway is, according to the updated HapMap releases,
44%, ranging from 21% to 86%. Therefore, we cannot rule out
completely the implication of common variation in these genes in
UCB susceptibility.
For common SNPs (MAF.0.05), our study is powered (90%) to
detect ORs$1.4 at a significance level of 0.05, assuming an
additive mode of inheritance. Therefore, the study is not
conclusive with OR,1.4. While this study represents one of the
largest assessments conducted till present, much larger studies will
be required to rule out smaller main effects associated with
common variants in the genes of this pathway. This is even more
important when subphenotype analyses are considered. We also
found no evidence of SNP-SNP interactions (permutation test p-
value$0.3) and SNP-smoking interactions (permutation test p-
value$0.07), although the power was even more limited to detect
these. According to the candidate pathway, the studied SNPs were
selected as tags; therefore, they were not correlated showing a low
LD. This fact, let us overcome a potential limitation affecting the
percentage of reproducibility when SNPs are high correlated.
Credit should also be given to this study, not only regarding its
large sample size, but also for its prospective nature and disease
representativeness, for the homogeneous methods applied to
collect information and biosamples by the participating centers,
for the integration of different type of information (sociodemo-
graphics, epidemiological, genetic, clinical and pathological, and
molecular), and for the comprehensive and innovative statistical
approaches applied to assess UCB susceptibility associated with a
highly candidate pathway.
In conclusion, using a comprehensive analysis accounting
different models and different approaches, we found no strong
evidence that common variants in the TP53 pathway are
associated with UCB risk. However, specific members of the
pathway, TP63 and SERPINB5 deserve of further exploration in
extended studies. On the other hand, our study suggests that it is
unlikely that TP53 Arg72Pro is implicated in the UCB in white
Europeans.
While biological sound, candidate pathway analysis have throw
limited acknowledge in the genetic susceptibility field of many
diseases. The reasons of this relative poor efficiency may be,
among others, the still lack of knowledge of all key components of
a given pathway, the introduction of noise by considering many
genes/variants without showing association, and the lack of
coverage of rare variants not tagged through this approach, in
addition to methodological explanations such as an impaired
statistical power. Scientists should review whether it is time to
dismiss this approach towards a more comprehensive strategy such
whole genome/exome sequencing in dissecting the genetic
architecture of complex diseases.
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